US 12,344,646 B2
Antibody-TNF α fusion protein and its preparation and applications
Zeling Cai, Shanghai (CN); and Yi Chen, Shanghai (CN)
Assigned to Bang Ding, Shanghai (CN)
Appl. No. 17/413,260
Filed by Bang Ding, Shanghai (CN)
PCT Filed Dec. 13, 2018, PCT No. PCT/CN2018/120839
§ 371(c)(1), (2) Date Jun. 11, 2021,
PCT Pub. No. WO2020/118605, PCT Pub. Date Jun. 18, 2020.
Prior Publication US 2022/0098262 A1, Mar. 31, 2022
Int. Cl. C07K 14/525 (2006.01); A61K 31/45 (2006.01); A61K 31/704 (2006.01); A61K 38/12 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC C07K 14/525 (2013.01) [A61K 31/45 (2013.01); A61K 31/704 (2013.01); A61K 38/12 (2013.01); A61K 38/191 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01)] 4 Claims
 
1. A fusion protein of an antibody and TNFα, comprising an antibody moiety and a TNFα moiety conjugated to the C-terminal of the heavy chain of said antibody,
wherein said fusion protein comprises: a heavy chain comprising the heavy chain of said antibody with said TNFα moiety linked at the C-terminal and optionally a signal peptide at N-terminal; and a light chain comprising the light chain of said antibody and optionally a signal peptide at N-terminal;
wherein the antibody moiety in the fusion protein is in the form of a full-length antibody;
wherein said antibody is specific to a tumor antigen, Her-2, the antibody is Trastuzumab, and said TNFα moiety is human TNFα.